Search peptides, terms, sources/
Research source · 2017

A second dose of kisspeptin-54 improves oocyte maturation in women at high risk of ovarian hyperstimulation syndrome: a Phase 2 randomized controlled trial

About this source

Kind
Research
Design
Human clinical trial, RCT
Population
62 women aged 18 to 34 at high OHSS risk, Hammersmith Hospital IVF unit, London
Sample size
62
Primary or secondary
primary
Peer review
peer reviewed
Retraction status
None known
Date checked
13 August 2026

Limitations

Single dose-interval tested; oocyte retrieval timing may not capture the full benefit window per authors; underpowered for implantation-rate comparisons.

Cited in

Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.